1. Home
  2. MESO vs GIII Comparison

MESO vs GIII Comparison

Compare MESO & GIII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MESO
  • GIII
  • Stock Information
  • Founded
  • MESO 2004
  • GIII 1956
  • Country
  • MESO Australia
  • GIII United States
  • Employees
  • MESO N/A
  • GIII N/A
  • Industry
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • GIII Apparel
  • Sector
  • MESO Health Care
  • GIII Consumer Discretionary
  • Exchange
  • MESO Nasdaq
  • GIII Nasdaq
  • Market Cap
  • MESO 1.4B
  • GIII 1.2B
  • IPO Year
  • MESO N/A
  • GIII 1989
  • Fundamental
  • Price
  • MESO $10.44
  • GIII $21.96
  • Analyst Decision
  • MESO Buy
  • GIII Buy
  • Analyst Count
  • MESO 4
  • GIII 6
  • Target Price
  • MESO $18.00
  • GIII $28.83
  • AVG Volume (30 Days)
  • MESO 191.2K
  • GIII 989.2K
  • Earning Date
  • MESO 02-26-2025
  • GIII 06-06-2025
  • Dividend Yield
  • MESO N/A
  • GIII N/A
  • EPS Growth
  • MESO N/A
  • GIII 12.17
  • EPS
  • MESO N/A
  • GIII 4.28
  • Revenue
  • MESO $5,670,000.00
  • GIII $3,154,658,000.00
  • Revenue This Year
  • MESO $178.09
  • GIII $0.32
  • Revenue Next Year
  • MESO $305.06
  • GIII N/A
  • P/E Ratio
  • MESO N/A
  • GIII $5.02
  • Revenue Growth
  • MESO N/A
  • GIII 1.72
  • 52 Week Low
  • MESO $5.78
  • GIII $20.33
  • 52 Week High
  • MESO $22.00
  • GIII $36.18
  • Technical
  • Relative Strength Index (RSI)
  • MESO 40.14
  • GIII 34.22
  • Support Level
  • MESO $11.70
  • GIII $20.33
  • Resistance Level
  • MESO $12.37
  • GIII $21.71
  • Average True Range (ATR)
  • MESO 0.44
  • GIII 1.04
  • MACD
  • MESO -0.04
  • GIII -0.43
  • Stochastic Oscillator
  • MESO 6.88
  • GIII 18.15

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

About GIII G-III Apparel Group LTD.

G-III Apparel Group Ltd is a textile company. It makes a wide range of apparel, footwear, and accessories that it sells under its own brands, licensed brands, and private-label brands. G-III has a substantial portfolio for licensed and proprietary brands, anchored by five global power brands: DKNY, Donna Karan, Calvin Klein, Tommy Hilfiger, and Karl Lagerfeld. The company has two reportable operations: Wholesale Operations and Retail Operations. The Wholesale operations segment includes sales of products under brands licensed by from third parties, as well as sales of products under its own brands and private label brands. The retail operations segment consists of Wilsons Leather, G.H. Bass, and DKNY retail stores. It derives majority of its revenues from Wholesale operations.

Share on Social Networks: